Growing European Pharmaceutical Organization Awards $1.2 Million Study Extension to eResearchTechnology for Cardiac Safety Monit
17 March 2004 - 1:01AM
PR Newswire (US)
Growing European Pharmaceutical Organization Awards $1.2 Million
Study Extension to eResearchTechnology for Cardiac Safety
Monitoring and Information Distribution Services Overall Agreement
Now Totals More Than $2.7 Million for Thorough Phase I ECG Study
PHILADELPHIA, March 16 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an
agreement for more than $1.2 million in additional cardiac safety
monitoring and services from a growing European pharmaceutical
organization for one of its drug candidates in clinical
development. The additional award brings to $2.7 million the total
services contracted toeRT for this single clinical trial. The
agreement covers an extension to an extensive Phase I study for
which eRT was already providing comprehensive support including the
provision, training and ongoing assistance required for effective
use of digital 12-lead Holter equipment designed to facilitate
24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The study extension is targeted
for completion over a 90-day period. "After careful consideration,
this sponsor elected to further enhance the cardiac safety profile
for this important study, and eRT stands ready to provide the
capacity and throughput required to process a significantly
increased number of ECGs within a compressed timeframe," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "eRT's unique approach to delivering
comprehensive services for successful execution of ThoroughPhase I
ECG studies, including close partnerships with Clinical
Pharmacology Units for study conduct, enabled the flexibility
required to immediately meet this increased demand." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and servicesto evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in thesponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden, Hayden Communications,
+1-760-487-1137, for eResearchTechnology, Inc. Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles